Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

被引：0

作者：

Stefanie Förderreuther

Qi Zhang

Virginia L. Stauffer

Sheena K. Aurora

Miguel J. A. Láinez

机构：

[1] Ludwig Maximilian University,Department of Neurology

[2] Sanofi,undefined

[3] Eli Lilly and Company,undefined

[4] Lilly Corporate Center,undefined

[5] Hospital Clínico Universitario,undefined

[6] Universidad Católica de Valencia,undefined

来源：

The Journal of Headache and Pain | 2018年 / 19卷

关键词：

Galcanezumab; Migraine; Preventive; Persistence; Maintenance;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
Foerderreuther, Stefanie
Zhang, Qi
Stauffer, Virginia L.
Aurora, Sheena K.
Lainez, Miguel J. A.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[2] GALCANEZUMAB EFFECTS IN ADULT PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE ARE PERSISTENT: DATA FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVOLVE-1, EVOLVE-2, AND REGAIN STUDIES
Aurora, S.
Zhang, Q.
Stauffer, V.
CEPHALALGIA, 2018, 38 : 50 - 51
[3] Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo controlled EVOLVE-1, EVOLVE-2 and REGAIN studies
Aurora, Sheena K.
Zhang, Qi
Stauffer, Virginia L.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[4] Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
Nichols, Russell
Doty, Erin
Sacco, Sara
Ruff, Dustin
Pearlman, Eric
Aurora, Sheena K.
HEADACHE, 2019, 59 (02): : 192 - 204
[5] Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies
Oakes, Tina M.
Kovacs, Richard
Rosen, Noah
Doty, Erin
Kemmer, Phebe
Aurora, Sheena K.
Camporeale, Angelo
HEADACHE, 2020, 60 (01): : 110 - 123
[6] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
Jessica Ailani
J. Scott Andrews
Mallikarjuna Rettiganti
Robert A. Nicholson
The Journal of Headache and Pain, 2020, 21
[7] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
Ailani, Jessica
Andrews, J. Scott
Rettiganti, Mallikarjuna
Nicholson, Robert A.
JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
[8] Persistence of Effect of Galcanezumab in Patients with Episodic or Chronic Migraine: Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1,-2 and REGAIN Studies
Aurora, S.
Zhang, Q.
HEADACHE, 2018, 58 : 177 - 178
[9] Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
Nichols, Russell M.
Ruff, Dustin
Pearlman, Eric
Aurora, Sheena K.
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[10] Analysis of Initial Non-Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
Nichols, R.
Ruff, D.
Pearlman, E.
Aurora, S.
HEADACHE, 2018, 58 : 173 - 174

← 1 2 3 4 5 →